Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13349487 | 0.85 | ALDH1A1 (0.39) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL21321209 | 0.84 | ALDH1A1 (0.39) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3575583 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3584740 | 0.80 | ALDH1A1 (0.45) | ALDH1A1MAPK1SMN1; SMN2MAPTRECQL | |
| SCHEMBL3582319 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3586175 | 0.78 | ALDH1A1 (0.45) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3576294 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3576300 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3576296 | 0.78 | ALDH1A1 (0.44) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL3580185 | 0.76 | ALDH1A1 (0.43) | ALDH1A1MAPK1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118076-B1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO SA (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-8614215-B2 | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) | MERCK SERONO SA (CH) | 2013-12-24 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | MERCK SERONO SA (CH) | 2010-06-03 | — | — | US | disclosed |
| WO-2008101979-A1 | QUINOXALINE COMPOUNDS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137308-A1 | Quinoxaline Compounds and Use Thereof | PFKP, PDXK, PF4 | ALDH1A1 577/4885MAPK1 2681/4885SMN1; SMN2 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.